温阳解毒化瘀法对肝衰竭IETM非阳黄证的干预机制及临床疗效研究
|
摘要
研究一阴黄证大鼠IETM模型的建立
目的：
联合D-半乳糖胺(D-gal)腹腔注射及大黄煎剂灌胃诱导建立肝衰竭IETM阴黄证实验动物模型。
方法：
SD大鼠68只,随机分为Ⅰ(正常组)、Ⅱ(阳黄证对照组)和Ⅲ(阴黄证组),Ⅰ组6只,Ⅱ、Ⅲ组每组各31只。实验动物分组后,单笼饲养,自由食水,同等条件喂养3天,各组动物称重、测肛温,从第4天起施加处理因素。Ⅱ组大鼠,将其置于湿热造模环境下(造模箱温度30-32℃,R T大于95%)；Ⅲ组大鼠,将其置于寒湿造模环境下(造模箱温度1-6℃,RT大于95%)。Ⅲ组予400%大黄煎剂按照50ml/kg灌胃,2次/天；Ⅱ组予1：1的5%葡糖糖和猪油脂混合液20ml/kg灌胃,2次/天；Ⅰ组予生理盐水灌胃50ml/kg,2次/天。阳黄、阴黄证造模21天。21天后以D-gal1.8g/kg腹腔注射Ⅱ、Ⅲ组建立肝衰竭IETM模型,正常组腹腔注射等量生理盐水,24h、48h分别观察各组大鼠死亡率、肝功能(ALT、AST、TBIL)、肝组织病理改变、门静脉内毒素水平、直肠内粪便肠道菌群水平。
结果：
1.一般情况：Ⅰ组大鼠无死亡。Ⅱ组、Ⅲ组大鼠死亡率分别为20%、30%。
2.肝功能结果：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠ALT、AST、TBIL均明显升高,差异有统计学意义(p<0.01),Ⅲ组较Ⅱ组ALT、AST、 TBIL增加更为明显,差异有统计学意义(p<0.05)。
3.肝组织病理结果：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠肝组织损伤明显加重,各组间比较病理积分,差异有统计学意义(p<0.05)。Ⅱ组、Ⅲ组大鼠肝组织损伤程度达到肝衰竭肝组织损伤诊断水平,肝组织病理积分以Ⅲ组最高,两时间点病理积分组间比较差异无统计学意义p>0.05)。
4.血浆内毒素：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠血浆内毒素明显升高,差异有统计学意义(p<0.01)；Ⅲ组、Ⅲ组大鼠组间门静脉内毒素比较差异有统计学意义(p<0.05)。
5.粪便肠道菌群水平：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠肠球菌、肠杆菌均明显增多,差异有统计学意义(p<0.01)；双歧杆菌、乳酸杆菌均减少,差异有统计学意义(p<0.05)；Ⅱ组、Ⅲ组大鼠组间比较,肠球菌、肠杆菌、双歧杆菌差异有统计学意义(p<0.05),乳酸杆菌差异无统计学意义(p>0.05)。
结论：
联合寒湿造模环境、大黄煎剂灌胃及腹腔注射D-gal方法可诱导建立阴黄证IETM模型。
研究二温阳解毒化瘀法对阴黄证肝衰竭IETM大鼠内毒素、细胞因子的影响
目的：
1.研究温阳解毒化瘀法对阴黄证肝衰竭IETM大鼠IL-6、C-met蛋白免疫表达等表达影响。
2.研究温阳解毒化瘀法干预后阴黄证肝衰竭IETM大鼠肠道菌群、血浆内毒素的变化。
方法：
SD大鼠86只,随机分为阴黄证肝衰竭IETM模型组(Ⅰ组)、温阳解毒化瘀方低剂量组(Ⅱ组)、温阳解毒化瘀方中剂量组(Ⅲ组)、温阳解毒化瘀方高剂量组(Ⅳ组),每组各20只,正常组(Ⅴ组)大鼠6只。Ⅱ、Ⅲ、Ⅳ组大鼠于造模前6天予温阳解毒化瘀方不同剂量灌胃,Ⅰ组大鼠以生理盐水灌胃,2次/天,直至处死。造模21天后I、II、III、IV组予D-gal1.8g/kg腹腔注射、大黄煎剂灌胃建立阴黄证IETM模型；Ⅴ组大鼠正常饮食。观察各组大鼠在造模后24h、48h死亡率,各组大鼠同时对肝功能(ALT、AST、TBIL)、肝脏组织病理、血浆内毒素、肠道菌群、肝组织IL-6、C-met蛋白免疫表达等进行检测。
结果：
1.死亡率：Ⅰ组大鼠死亡率为32%；Ⅱ、Ⅲ、Ⅳ组大鼠死亡率随温阳解毒化瘀方剂量增加逐渐下降,各组死亡率为23%、20%、15%。
2.肝功能：与Ⅰ组比较,Ⅱ、Ⅲ、Ⅳ组大鼠ALT、AST、TBIL均降低,其中Ⅳ组与Ⅰ组组间比较,差异有统计学意义(p<0.01)。
3.肝组织病理结果：与Ⅰ组比较,Ⅱ、Ⅲ、Ⅳ组肝组织病理结果显示,损伤均减轻,其中Ⅳ组与Ⅰ组肝组织病理评分,差异有统计学意义(p<0.05)。
4.血浆内毒素：与Ⅰ组比较,Ⅱ、Ⅲ、Ⅳ组内毒素水平均减轻,其中Ⅳ组与Ⅰ组组间差异有统计学意义(p<0.05)。
5.肠道菌群水平：与Ⅰ组比较,Ⅱ组、Ⅲ、Ⅳ组大鼠肠球菌、肠杆菌均增多,差异有统计学意义(p<0.01)；双歧杆菌、乳酸杆菌均减少,差异有统计学意义(p<0.05)；Ⅱ组、Ⅲ组分别与Ⅳ组大鼠组间比较,肠球菌、肠杆菌、双歧杆菌差异有统计学意义(p<0.05),乳酸杆菌差异无统计学意义(p>0.05)。Ⅱ组、Ⅲ组组间比较差异无统计学意义(p>0.05)。
6.肝组织IL-6水平变化：与Ⅰ组比较,Ⅱ组、Ⅲ组、Ⅳ组大鼠IL-6水平明显下降,差异有统计学意义(p<0.05)。
7.C-met蛋白免疫组化：与Ⅰ组比较,Ⅱ组、Ⅲ组、Ⅳ组.C-met阳性面积均明显增高,差异有统计学意义(P<0.01)； Ⅳ组与Ⅱ组、Ⅲ组两两比较,Ⅳ组.C-met阳性面积较Ⅱ组、Ⅲ组增高,差异有统计学意义(P<0.05)。
结论：
1.温阳解毒化瘀方能降低肝衰竭IETM阴黄证大鼠死亡率,改善肝功能、减轻肝组织病理情况。
2.温阳解毒化瘀方作用于肝衰竭IETM阴黄证的机制可能是通过(1)降低血浆内毒素的吸收；(2)诱导免疫信号激活；促进肝细胞增生；(3)调节肠道菌群来实现。
研究三温阳解毒化瘀法对乙型肝炎相关性肝衰竭阴黄证及阴阳黄证患者的影响
目的：
通过对入选60例乙型肝炎相关性肝衰竭患者中西结合治疗的分析,评估温阳解毒化瘀法对乙型肝炎相关性肝衰竭非阳黄证患者疗效。
方法：
入选病例按照中医辨证为非阳黄证组(阴黄证和阴阳黄证),按照随机数字表分为治疗组、对照组,两组患者均予常规保肝、护肝、护胃、改善肝脏微循环、抗病毒、对症支持治疗等,试验组在此基础上予温阳解毒化瘀颗粒剂,对照组在此基础上给予中药模拟剂治疗。用药8周后,对两组患者进行疗效评价。
结果：
两组治疗后TBIL、PTA、肠道内毒素等组间比较,差异有统计学意义(P<0.05),两组组内治疗前后比较,差异有统计学意义(P<0.05)。
结论：
温阳解毒化瘀法治疗乙型肝炎相关性肝衰竭患者,可以改善症状,提高疗效。
Study one Yin yellow card IETM model in rats
Objectives:
Joint D-galactosamine (D-gal) intraperitoneal injection and rhubarb decoction lavage induced liver failure IETM Yin yellow card experimental animal model.
Methods:
68SD rats, were randomly divided into three groups, Ⅰ (normal control group), Ⅱ(yang yellow card group)and Ⅲ(Yin yellow card group). Normal group6, Ⅱ, Ⅲ groups each group only31. After experimental animal group, single cage, the free water, the same article3days, each animal weighing, measuring the anus temperature, from4days of the processing factors. Ⅱ group of rats, made mould to place it in hot and humid environment, Ⅲ group of rats, puts the cold dampness building environment. Group Ⅲ to400%rhubarb decoction according to the50ml/kg to fill the stomach,2times/day, Ⅱ group to1:15%sugar and pig oil mix20ml/kg to fill the stomach,2times/day; I set to saline to fill the stomach,2times/day. Hot and humid, cold dampness syndrome made mould for21days.21days will be D-gal intraperitoneal injection of1.8g/kg group Ⅱ and Ⅲ IETM liver failure model is established. By intraperitoneal injection of normal group amount of saline solution, After24h,48h were observed between groups of rats mortality, Liver function(ALT、AST、TBIL), Pathological changes of the liver tissue, Endotoxin level of portal vein, Rectum waste levels of intestinal flora.
Results:
1. General situation:group I rats without death. II, III group rats mortality respectively:20%,30%.
2. Results of liver function:As a reference in group I, II and III group rats ALT, AST and TBIL were significantly increased, the difference was statistically significant (p<0.01). As a reference in group III, II group of ALT, AST and TBIL increased more obviously, the difference was statistically significant (p<0.05).
3. Liver tissue pathology results:as a reference in group I, group III in the rat liver tissue damage is aggravating, obviously pathological integral is compared between each group, the difference was statistically significant (p<0.05). II, III group in the rat liver tissue damage to liver failure diagnosis of liver tissue damage level and liver tissue pathology the highest score in group III, comparing differences between two time points pathological integral group has no statistical significance (p>0.05).
4. Portal vein endotoxin:As a reference in group I, II, III group rats with portal vein endotoxin obviously increases, the difference was statistically significant (p<0.01); Ⅱ, III group rats portal vein endotoxin comparative differences between groups was statistically significant (p<0.05).
5.Excrement and urine levels of intestinal flora:As a reference in group I, enterococcus, Ⅱ, III group rats enterbacteriaceae were significantly increased, the difference was statistically significant (p<0.01); Bifidobacterium and lactobacillus were reduced, the difference was statistically significant (p<0.05);Ⅱ, III group comparison between groups of rats, enterococcus, e. coli and bifidobacteria difference was statistically significant (p<0.05), the difference of lactobacillus has no statistical significance (p>0.05).
Conclussion:
Combined cold dampness building environment, rhubarb decoction lavage and intraperitoneal injection of D-gal method to induce Yin yellow card IETM model is set up.
Study two This toxin and blood endotoxin of IETM Yin yellow card liver failure rats, the influence of cytokines
Objectives:
1.Research explored blood detoxification method of IETM Yin yellow card liver failure rat IL-6, C-met immune protein expression and expression.
2. Study this toxin and blood Yin yellow card to liver failure after intervention IETM rat intestinal flora, the change of plasma endotoxin.
Methods:
86SD rats, Were randomly divided into Yin yellow card to liver failure IETM model group (group I), explored the detoxification of blood low dose group (group II), explored the detoxification of blood in the dose group (group III), explored the detoxifyication of blood high dose group (group IV), each group of20, Normal6(group V) in rats. II, III, IV group6days prior to the building of rats with different blood party explored detoxified dose lavage, I group of rats with normal saline lavage,2times/day, until death. Building21days in group I, II, III, IV to D-gal intraperitoneal injection of1.8g/kg Yin yellow card IETM model is set up; V group rats normal diet. Observed between groups of rats in24h,48h after building mortality, groups of rats and liver function (ALT, AST,TBIL) and liver tissue pathology, plasma endotoxin, intestinal flora, IL-6, C-the liver tissue tested met the immune protein expression and so on.
Results:
1.Mortality:I group rats mortality rate of32%; Ⅱ, Ⅲ, Ⅳ group rats mortality declined gradually with the increase of this blood detoxification party dose, groups of mortality was23%,20%and15%, respectively.
2. Liver function:compared with group Ⅰ, Ⅱ, Ⅲ, IV group rats ALT, AST, TBIL is reduced, the IV group and the comparison between the way, I was statistically significant difference (p<0.01).
3. Liver tissue pathology results:compared with group Ⅰ, Ⅱ, Ⅲ, Ⅳ group, according to the results of liver tissue pathology damage reduce, only IV group and the group I liver histopathologic grading, the difference was statistically significant (p<0.05).
4. Plasma endotoxin:compared with group Ⅰ, Ⅱ, Ⅲ, IV group, the level of endotoxin was reduced, only high dose group and the difference between model way was statistically significant (p<0.05).
5. Fecal intestinal flora level:compared with group Ⅰ, Ⅱ, Ⅲ, Ⅳ group rat intestinal bacteria, e. coli were increased, the difference was statistically significant(p<0.01); BifidoBacterium and lactobacillus were reduced, the difference was statistically significant (p<0.05); Ⅱ, Ⅲ and IV respectiveely compared between group rats, enterococcus, e. coli and bifidobacteria difference was statistically significant (p<0.05), the difference of lactobacillus has no statistical significance (p>0.05). Group Ⅱ, Ⅲ, comparing differences between way has no statistical significance (p>0.05).
6. IL-6level changes:the liver tissue compared with group Ⅰ, Ⅱ, Ⅲ, Ⅳ group rats IL-6levels increased significantly, the difference was statistically significant (p<0.05).
7. C-met protein immunohistochemical:compared with group Ⅰ, Ⅱ, Ⅲ, IV group. C-met positive area were significantly increased, the difference was statistically significant (P<0.01); IV group compared with two Ⅱ, Ⅲ, IV group. C-met positive area is higher than Ⅱ, Ⅲ, the difference was statistically significant (P<0.05).
Conclussion:
1. Using this blood detoxification reduce liver failure IETM Yin yellow card mortality in rats, improve liver function, reduce liver tissue pathological situation.
2. This blood detoxification side effects on liver failure mechanism of IETM Yin yellow card may be by (1) reduce the absorption of the plasma endotoxin;(2) inducing immune signal activation; To promote the increment of liver cell;(3) regulating intestinal flora; To implement.
Study three Wenyang Jiedu Huayu method for patients with hepatitis B liver failure correlation Yin yellow card and Yin Yang yellow card
Objectives:
Through selected60cases of patients with hepatitis B liver failure correlation the analysis of the combined therapy of Chinese and western, evaluate this toxin and blood in patients with hepatitis B liver failure correlation Yin yellow card and Yin Yang yellow card curative effect.
Methods:
Selected cases according to syndrome differentiation of TCM into the Yin yellow card and Yin Yang yellow card groups. And according to random number table is divided into the experimental group and control group, two groups of patients were in normal liver, protection of liver, stomach, improve the hepatic microcirculation, antiviral, symptomatic treatment, etc.on the basis of the experimental group to this blood detoxification granules, the control group on the basis of the simulation agent treatment with traditional Chinese medicine. After eight weeks, to evaluate curative effect of two groups of patients.
Results:
The two groups after treatment of liver TBIL, PTA, gut endotoxin comparison between groups, such as difference was statistically significant (P>0.05), inside two way comparison before and after the treatment, the difference was statistically significant (P<0.05).
Conclussion:
Combining this detoxification treated patients with hepatitis B liver failure correlation method, can improve symptoms, improve curative effect.
目的：
联合D-半乳糖胺(D-gal)腹腔注射及大黄煎剂灌胃诱导建立肝衰竭IETM阴黄证实验动物模型。
方法：
SD大鼠68只,随机分为Ⅰ(正常组)、Ⅱ(阳黄证对照组)和Ⅲ(阴黄证组),Ⅰ组6只,Ⅱ、Ⅲ组每组各31只。实验动物分组后,单笼饲养,自由食水,同等条件喂养3天,各组动物称重、测肛温,从第4天起施加处理因素。Ⅱ组大鼠,将其置于湿热造模环境下(造模箱温度30-32℃,R T大于95%)；Ⅲ组大鼠,将其置于寒湿造模环境下(造模箱温度1-6℃,RT大于95%)。Ⅲ组予400%大黄煎剂按照50ml/kg灌胃,2次/天；Ⅱ组予1：1的5%葡糖糖和猪油脂混合液20ml/kg灌胃,2次/天；Ⅰ组予生理盐水灌胃50ml/kg,2次/天。阳黄、阴黄证造模21天。21天后以D-gal1.8g/kg腹腔注射Ⅱ、Ⅲ组建立肝衰竭IETM模型,正常组腹腔注射等量生理盐水,24h、48h分别观察各组大鼠死亡率、肝功能(ALT、AST、TBIL)、肝组织病理改变、门静脉内毒素水平、直肠内粪便肠道菌群水平。
结果：
1.一般情况：Ⅰ组大鼠无死亡。Ⅱ组、Ⅲ组大鼠死亡率分别为20%、30%。
2.肝功能结果：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠ALT、AST、TBIL均明显升高,差异有统计学意义(p<0.01),Ⅲ组较Ⅱ组ALT、AST、 TBIL增加更为明显,差异有统计学意义(p<0.05)。
3.肝组织病理结果：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠肝组织损伤明显加重,各组间比较病理积分,差异有统计学意义(p<0.05)。Ⅱ组、Ⅲ组大鼠肝组织损伤程度达到肝衰竭肝组织损伤诊断水平,肝组织病理积分以Ⅲ组最高,两时间点病理积分组间比较差异无统计学意义p>0.05)。
4.血浆内毒素：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠血浆内毒素明显升高,差异有统计学意义(p<0.01)；Ⅲ组、Ⅲ组大鼠组间门静脉内毒素比较差异有统计学意义(p<0.05)。
5.粪便肠道菌群水平：以Ⅰ组作参照,Ⅱ组、Ⅲ组大鼠肠球菌、肠杆菌均明显增多,差异有统计学意义(p<0.01)；双歧杆菌、乳酸杆菌均减少,差异有统计学意义(p<0.05)；Ⅱ组、Ⅲ组大鼠组间比较,肠球菌、肠杆菌、双歧杆菌差异有统计学意义(p<0.05),乳酸杆菌差异无统计学意义(p>0.05)。
结论：
联合寒湿造模环境、大黄煎剂灌胃及腹腔注射D-gal方法可诱导建立阴黄证IETM模型。
研究二温阳解毒化瘀法对阴黄证肝衰竭IETM大鼠内毒素、细胞因子的影响
目的：
1.研究温阳解毒化瘀法对阴黄证肝衰竭IETM大鼠IL-6、C-met蛋白免疫表达等表达影响。
2.研究温阳解毒化瘀法干预后阴黄证肝衰竭IETM大鼠肠道菌群、血浆内毒素的变化。
方法：
SD大鼠86只,随机分为阴黄证肝衰竭IETM模型组(Ⅰ组)、温阳解毒化瘀方低剂量组(Ⅱ组)、温阳解毒化瘀方中剂量组(Ⅲ组)、温阳解毒化瘀方高剂量组(Ⅳ组),每组各20只,正常组(Ⅴ组)大鼠6只。Ⅱ、Ⅲ、Ⅳ组大鼠于造模前6天予温阳解毒化瘀方不同剂量灌胃,Ⅰ组大鼠以生理盐水灌胃,2次/天,直至处死。造模21天后I、II、III、IV组予D-gal1.8g/kg腹腔注射、大黄煎剂灌胃建立阴黄证IETM模型；Ⅴ组大鼠正常饮食。观察各组大鼠在造模后24h、48h死亡率,各组大鼠同时对肝功能(ALT、AST、TBIL)、肝脏组织病理、血浆内毒素、肠道菌群、肝组织IL-6、C-met蛋白免疫表达等进行检测。
结果：
1.死亡率：Ⅰ组大鼠死亡率为32%；Ⅱ、Ⅲ、Ⅳ组大鼠死亡率随温阳解毒化瘀方剂量增加逐渐下降,各组死亡率为23%、20%、15%。
2.肝功能：与Ⅰ组比较,Ⅱ、Ⅲ、Ⅳ组大鼠ALT、AST、TBIL均降低,其中Ⅳ组与Ⅰ组组间比较,差异有统计学意义(p<0.01)。
3.肝组织病理结果：与Ⅰ组比较,Ⅱ、Ⅲ、Ⅳ组肝组织病理结果显示,损伤均减轻,其中Ⅳ组与Ⅰ组肝组织病理评分,差异有统计学意义(p<0.05)。
4.血浆内毒素：与Ⅰ组比较,Ⅱ、Ⅲ、Ⅳ组内毒素水平均减轻,其中Ⅳ组与Ⅰ组组间差异有统计学意义(p<0.05)。
5.肠道菌群水平：与Ⅰ组比较,Ⅱ组、Ⅲ、Ⅳ组大鼠肠球菌、肠杆菌均增多,差异有统计学意义(p<0.01)；双歧杆菌、乳酸杆菌均减少,差异有统计学意义(p<0.05)；Ⅱ组、Ⅲ组分别与Ⅳ组大鼠组间比较,肠球菌、肠杆菌、双歧杆菌差异有统计学意义(p<0.05),乳酸杆菌差异无统计学意义(p>0.05)。Ⅱ组、Ⅲ组组间比较差异无统计学意义(p>0.05)。
6.肝组织IL-6水平变化：与Ⅰ组比较,Ⅱ组、Ⅲ组、Ⅳ组大鼠IL-6水平明显下降,差异有统计学意义(p<0.05)。
7.C-met蛋白免疫组化：与Ⅰ组比较,Ⅱ组、Ⅲ组、Ⅳ组.C-met阳性面积均明显增高,差异有统计学意义(P<0.01)； Ⅳ组与Ⅱ组、Ⅲ组两两比较,Ⅳ组.C-met阳性面积较Ⅱ组、Ⅲ组增高,差异有统计学意义(P<0.05)。
结论：
1.温阳解毒化瘀方能降低肝衰竭IETM阴黄证大鼠死亡率,改善肝功能、减轻肝组织病理情况。
2.温阳解毒化瘀方作用于肝衰竭IETM阴黄证的机制可能是通过(1)降低血浆内毒素的吸收；(2)诱导免疫信号激活；促进肝细胞增生；(3)调节肠道菌群来实现。
研究三温阳解毒化瘀法对乙型肝炎相关性肝衰竭阴黄证及阴阳黄证患者的影响
目的：
通过对入选60例乙型肝炎相关性肝衰竭患者中西结合治疗的分析,评估温阳解毒化瘀法对乙型肝炎相关性肝衰竭非阳黄证患者疗效。
方法：
入选病例按照中医辨证为非阳黄证组(阴黄证和阴阳黄证),按照随机数字表分为治疗组、对照组,两组患者均予常规保肝、护肝、护胃、改善肝脏微循环、抗病毒、对症支持治疗等,试验组在此基础上予温阳解毒化瘀颗粒剂,对照组在此基础上给予中药模拟剂治疗。用药8周后,对两组患者进行疗效评价。
结果：
两组治疗后TBIL、PTA、肠道内毒素等组间比较,差异有统计学意义(P<0.05),两组组内治疗前后比较,差异有统计学意义(P<0.05)。
结论：
温阳解毒化瘀法治疗乙型肝炎相关性肝衰竭患者,可以改善症状,提高疗效。
Study one Yin yellow card IETM model in rats
Objectives:
Joint D-galactosamine (D-gal) intraperitoneal injection and rhubarb decoction lavage induced liver failure IETM Yin yellow card experimental animal model.
Methods:
68SD rats, were randomly divided into three groups, Ⅰ (normal control group), Ⅱ(yang yellow card group)and Ⅲ(Yin yellow card group). Normal group6, Ⅱ, Ⅲ groups each group only31. After experimental animal group, single cage, the free water, the same article3days, each animal weighing, measuring the anus temperature, from4days of the processing factors. Ⅱ group of rats, made mould to place it in hot and humid environment, Ⅲ group of rats, puts the cold dampness building environment. Group Ⅲ to400%rhubarb decoction according to the50ml/kg to fill the stomach,2times/day, Ⅱ group to1:15%sugar and pig oil mix20ml/kg to fill the stomach,2times/day; I set to saline to fill the stomach,2times/day. Hot and humid, cold dampness syndrome made mould for21days.21days will be D-gal intraperitoneal injection of1.8g/kg group Ⅱ and Ⅲ IETM liver failure model is established. By intraperitoneal injection of normal group amount of saline solution, After24h,48h were observed between groups of rats mortality, Liver function(ALT、AST、TBIL), Pathological changes of the liver tissue, Endotoxin level of portal vein, Rectum waste levels of intestinal flora.
Results:
1. General situation:group I rats without death. II, III group rats mortality respectively:20%,30%.
2. Results of liver function:As a reference in group I, II and III group rats ALT, AST and TBIL were significantly increased, the difference was statistically significant (p<0.01). As a reference in group III, II group of ALT, AST and TBIL increased more obviously, the difference was statistically significant (p<0.05).
3. Liver tissue pathology results:as a reference in group I, group III in the rat liver tissue damage is aggravating, obviously pathological integral is compared between each group, the difference was statistically significant (p<0.05). II, III group in the rat liver tissue damage to liver failure diagnosis of liver tissue damage level and liver tissue pathology the highest score in group III, comparing differences between two time points pathological integral group has no statistical significance (p>0.05).
4. Portal vein endotoxin:As a reference in group I, II, III group rats with portal vein endotoxin obviously increases, the difference was statistically significant (p<0.01); Ⅱ, III group rats portal vein endotoxin comparative differences between groups was statistically significant (p<0.05).
5.Excrement and urine levels of intestinal flora:As a reference in group I, enterococcus, Ⅱ, III group rats enterbacteriaceae were significantly increased, the difference was statistically significant (p<0.01); Bifidobacterium and lactobacillus were reduced, the difference was statistically significant (p<0.05);Ⅱ, III group comparison between groups of rats, enterococcus, e. coli and bifidobacteria difference was statistically significant (p<0.05), the difference of lactobacillus has no statistical significance (p>0.05).
Conclussion:
Combined cold dampness building environment, rhubarb decoction lavage and intraperitoneal injection of D-gal method to induce Yin yellow card IETM model is set up.
Study two This toxin and blood endotoxin of IETM Yin yellow card liver failure rats, the influence of cytokines
Objectives:
1.Research explored blood detoxification method of IETM Yin yellow card liver failure rat IL-6, C-met immune protein expression and expression.
2. Study this toxin and blood Yin yellow card to liver failure after intervention IETM rat intestinal flora, the change of plasma endotoxin.
Methods:
86SD rats, Were randomly divided into Yin yellow card to liver failure IETM model group (group I), explored the detoxification of blood low dose group (group II), explored the detoxification of blood in the dose group (group III), explored the detoxifyication of blood high dose group (group IV), each group of20, Normal6(group V) in rats. II, III, IV group6days prior to the building of rats with different blood party explored detoxified dose lavage, I group of rats with normal saline lavage,2times/day, until death. Building21days in group I, II, III, IV to D-gal intraperitoneal injection of1.8g/kg Yin yellow card IETM model is set up; V group rats normal diet. Observed between groups of rats in24h,48h after building mortality, groups of rats and liver function (ALT, AST,TBIL) and liver tissue pathology, plasma endotoxin, intestinal flora, IL-6, C-the liver tissue tested met the immune protein expression and so on.
Results:
1.Mortality:I group rats mortality rate of32%; Ⅱ, Ⅲ, Ⅳ group rats mortality declined gradually with the increase of this blood detoxification party dose, groups of mortality was23%,20%and15%, respectively.
2. Liver function:compared with group Ⅰ, Ⅱ, Ⅲ, IV group rats ALT, AST, TBIL is reduced, the IV group and the comparison between the way, I was statistically significant difference (p<0.01).
3. Liver tissue pathology results:compared with group Ⅰ, Ⅱ, Ⅲ, Ⅳ group, according to the results of liver tissue pathology damage reduce, only IV group and the group I liver histopathologic grading, the difference was statistically significant (p<0.05).
4. Plasma endotoxin:compared with group Ⅰ, Ⅱ, Ⅲ, IV group, the level of endotoxin was reduced, only high dose group and the difference between model way was statistically significant (p<0.05).
5. Fecal intestinal flora level:compared with group Ⅰ, Ⅱ, Ⅲ, Ⅳ group rat intestinal bacteria, e. coli were increased, the difference was statistically significant(p<0.01); BifidoBacterium and lactobacillus were reduced, the difference was statistically significant (p<0.05); Ⅱ, Ⅲ and IV respectiveely compared between group rats, enterococcus, e. coli and bifidobacteria difference was statistically significant (p<0.05), the difference of lactobacillus has no statistical significance (p>0.05). Group Ⅱ, Ⅲ, comparing differences between way has no statistical significance (p>0.05).
6. IL-6level changes:the liver tissue compared with group Ⅰ, Ⅱ, Ⅲ, Ⅳ group rats IL-6levels increased significantly, the difference was statistically significant (p<0.05).
7. C-met protein immunohistochemical:compared with group Ⅰ, Ⅱ, Ⅲ, IV group. C-met positive area were significantly increased, the difference was statistically significant (P<0.01); IV group compared with two Ⅱ, Ⅲ, IV group. C-met positive area is higher than Ⅱ, Ⅲ, the difference was statistically significant (P<0.05).
Conclussion:
1. Using this blood detoxification reduce liver failure IETM Yin yellow card mortality in rats, improve liver function, reduce liver tissue pathological situation.
2. This blood detoxification side effects on liver failure mechanism of IETM Yin yellow card may be by (1) reduce the absorption of the plasma endotoxin;(2) inducing immune signal activation; To promote the increment of liver cell;(3) regulating intestinal flora; To implement.
Study three Wenyang Jiedu Huayu method for patients with hepatitis B liver failure correlation Yin yellow card and Yin Yang yellow card
Objectives:
Through selected60cases of patients with hepatitis B liver failure correlation the analysis of the combined therapy of Chinese and western, evaluate this toxin and blood in patients with hepatitis B liver failure correlation Yin yellow card and Yin Yang yellow card curative effect.
Methods:
Selected cases according to syndrome differentiation of TCM into the Yin yellow card and Yin Yang yellow card groups. And according to random number table is divided into the experimental group and control group, two groups of patients were in normal liver, protection of liver, stomach, improve the hepatic microcirculation, antiviral, symptomatic treatment, etc.on the basis of the experimental group to this blood detoxification granules, the control group on the basis of the simulation agent treatment with traditional Chinese medicine. After eight weeks, to evaluate curative effect of two groups of patients.
Results:
The two groups after treatment of liver TBIL, PTA, gut endotoxin comparison between groups, such as difference was statistically significant (P>0.05), inside two way comparison before and after the treatment, the difference was statistically significant (P<0.05).
Conclussion:
Combining this detoxification treated patients with hepatitis B liver failure correlation method, can improve symptoms, improve curative effect.
引文
[1]王慧芬,辛绍杰.肝衰竭诊治进展[M].北京：人民军医出版社,2011：28.
[2]wong V & M Chan HL. Severe acute exacerbation of chmnic hepatitis B:a unique presentation of a common disease.Gastroenterol Hepatol,2009,24:1179-1186.
[3]王柯心.慢性乙型重型肝炎不同分期的中医证候规律研究[D].广州,中山大学,硕士学位论文,2010年.
[4]李筠.慢性重型肝炎证候规律及中西医结合治疗方案研究研究报告.第二十次全国中西医结合肝病学术会议论文集,2011,27-29.
[5]黄建荣.重型乙型病毒性肝炎临床治疗进展.中华医学会第十五次全国病毒性肝炎和肝病学术会议论文集,2011,43-44.
[6]李筠.慢性重型肝炎证候规律及中西医结合治疗方案研究研究报告[R].第二十次全国中西医结合肝病学术会议论文集,2011,27-29.
[7]张雷,李筠.中医药治疗慢性重型肝炎临床研究进展.中西医结合肝病杂志,2010,20(5)：317-319.
[8]周意,贺希.慢性乙型重型肝炎中医证候与临床分期相关性研究[J].中医药导报,2010,5(16)：39-40.
[9]张涛,孙克伟,黄顺玲.基于特异性细胞免疫学机理阐述慢性重型肝炎中医黄疸论治.中西医结合肝病杂志,2010,20(5)：260-262.
[10]De-Wu Han.Intestinal endotoxemia as a pathogenetic mechanism in liver failure [J]世界胃肠病学杂志(英文版),2002,8(6)：961-965.
[11]熊焰、彭忠平、王书杰.慢性乙型重型肝炎辨证分型研究[J].中医药导报,2010,16(10)：6-9.
[12]张涛,孙克伟,陈斌等.黄疸病阴阳学说初探[J].新中医,2011,1(43)：4-6.
[13]李筠.慢性重型肝炎中医辨证与临床分期及预后分析[J].中西医结合肝病杂志,2007,17(6)：343-345.
[14]王荣田,樊新荣,黄碧群等.论证素辨证的层次性与实用性[J].中国中医药信息杂志,2008,15(8)：11-12.
[15]熊焰,彭忠平,王书杰.慢性乙型重型肝炎辨证分型研究[J].中医药导报,2010,10(16)6-9.
[16]陈斌,孙克伟,彭杰,等.基于阳黄-阴阳黄-阴黄辨证模式治疗慢性重型肝炎的临床观察[J].中国中医药科技,2012,19(1)：57-58.
[17]王立福,李筠,李丰衣等.中医辨证联合西药治疗慢加急性(亚急性)肝衰竭多 中心随机对照研究[J],中医杂志,2013,,54(22)：89-91.
[18]卢琳琳,陆伟,胡东胜等.急性肝衰竭大鼠肠粘膜屏障功能变化特点分析[J].山东医药,2012,52(39)：51-53.
[19]马文峰,周小舟,孙新锋等.中药治疗肝衰竭患者内毒素血症及其检测方法[J].中西医结合肝病杂志,2013,23,(2)：107-120.
[20]成薇婷,田德英.D-氨基半乳糖大鼠急性肝衰竭并发内毒素血症对糖代谢的影响极其机制[J].中西医结合肝病杂志,2010,20(1)：38-40.
[21]陈立艳,段钟平,周莉,等.肝功能衰竭模型的研究进展[J].中华肝脏病杂志.2010,18(10)：798-800.
[22]Wang LK,Wang LW,Li x,et al. Ethyl pyruvate prevents inflammatory factors release and dec-reases intestinal permeability in rats with D-galactosamine-induced acute liver failure[J]. Hepatob-iliary & Pancreatic Diseases International,2013,12(2):180-188.
[23]中华医学会感染病学分会肝衰竭与人工肝学组、中华医学会肝病学分会重型肝病与人工肝学组,肝衰竭诊治指南(2010版),中华肝脏病杂志,2011,21(3)：177-183.
[24]顾玉荣,慢加急肝衰竭肠道菌群与系统免疫相关性的初步探讨—慢加急肝衰竭(ACLF)不同时期肠道菌群、血浆内毒素、宿主系统免疫的动态变化及其相关性的初步探讨[D],广州,中山大学,硕士学位论文,2010.
[25]张赤志,曾浩,程良斌.阴黄证动物模型的建立及其意义[J],中国中医基础医学杂志,2000,6(7)：43-45。
[26]刘鹏,张涛,熊焰.乙型肝炎相关性肝衰竭中医证型研究现状[J]医学综述,2013,19(15)：2810-2812.
[27]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol.2010,25(5):1009-1012.
[28]李筠.内毒素在肝衰竭形成中的作用及中医药治疗[J].传染病信息,2010,(5)：260-262
[29]Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways:a dynamic duo. Annu Rev Physiol,2011,73:283-309.
[30]Hocher B,Heiden S,VonWebsky K,et al.Dual endothelin-converting enzyme/Neutral endopep-tidase blockade in rats with D-galactosamine-induced liver failure[J].Europea journal of medical research,2011,16 (6):275-279.
[31]施文娟,成军.HBV相关慢加急性肝功能衰竭患者血清IL-4和IL-6的表达及临 床意义[J].中华实验和临床感染病杂志,2013,7(2)：75-78.
[32]毛德文,张荣臻,邱华等.大黄、赤芍对术后肝衰竭大鼠血清IL-6的影响[J].辽宁中医杂志,2011,38(4)：757-758.
[33]王琳琳,陈秀奇.肠道-肝脏屏障的防御与内毒素移位的干预.临床儿科杂志,2010,28(10)：912-915.
[34]Matsumura F, Hartshorne DJ.Myosin phosphatase target subunit:Many roles in cell function. Biochem Biophys Res Commun,2008,369(1):149-156.
[35]杨宏志,肖阁敏,戴敏等.慢性乙型重型肝炎中医证候的动态观察.中药材,2010,33(9)：1519-1521.
[36]彭春荣,涂显琴,马超英.国内中医药治疗内毒素血症的研究进展.中华中医药学刊,2010,28(11)：2299-2230.
[37]李筠.内毒素在肝衰竭形成中的作用及中医药治疗.传染病信息,2010,23(5)：260-262.
[38]张涛,孙克伟,陈斌等.黄疸病阴阳学初探[J].新中医,2011,43(1)：4-6.
[39]王轩,陈斌,彭杰等.温阳解毒化瘀颗粒对肝衰竭内毒素血症大鼠肠道sIgA的影响[J].中西医结合肝病杂志,2013,23(3)：157-159.
[40]陈斌,王杰,彭杰等.温阳解毒化瘀颗粒对肝衰竭肠源性内毒素血症大鼠TLR4、NF-KB表达的影响[J].世界科学技术-中医药现代化,,2013,15,(5)：818-824.
[41]张强,孙凤霞.急性、亚急性肝衰竭临床研究进展[J].中华实验和临床感染病杂志,2012,6(2)：165-167.
[42]杨柳,赵瑛.川芎嗪对大鼠肠缺血再灌注损伤保护作用的实验研究[J].中国现代药物应用,2008,10(11)：11-15.
[43]梁育岑,段绍斌,刘郁等.大黄对肝部分切除大鼠血清与回肠组织SOD活性及回肠结构的影响[J].新疆医科大学学报,2010,33(1)：16-19.
[44]曲长江,王文丽,吴谙诏,秦微等.中医黄疸动物模型的建立[J].辽宁中医杂志,2005,32(10)：1087-1089.
[45]陈智.肝衰竭发生与发展过程中的免疫机制研究进展[J].中华肝脏病杂志,2012,20(10)：733-736.
[46]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats With Dga-lactosa mine induced acute severe liver injury[J].Gastroenterol Hepatol. 2009,24(6):1089-1094.
[47]伍玉南,孙克伟,彭建平,等.解毒化瘀温阳健脾与解毒化瘀益气健脾法治疗慢性重型肝炎的临床观察[J].中西医结合肝病杂志,2011,21(1)：4-7.
[48]过建春,荀运浩,段传荣等.慢性乙型重型肝炎中医证候规律研究.中华中医药学刊[J].2011,29(5)：969-971.
[49]彭杰,陈斌,孙克伟,等,慢性乙型重型肝炎“湿热-血瘀-脾虚”证候分布与演变特点的回顾性分析.中西医结合肝病杂志,2011,21(3)：135-138.
[50]张秋云等.慢乙肝、肝硬化、乙型慢重肝黄疸病的证候规律研究[J].北京中医药,2009,12(28)：976-978.
[51]周意,贺希.慢性乙型重型肝炎中医证候与临床分期相关性研究[J].中医药导报,2010,5(16)：39-40.
[52]聂广,余绍勇,江福生等.重型肝炎中医辨证分型标准的初步研究[J].中国中西医结合急救杂志,2001,3(8)：172-176.
[53]金晓东,谭兰香等.慢性重型肝炎中医证型与肝功能及PTA相关性研究[J].国医论坛,2011,4(26)：18-19.
[54]龙富立,毛德文等.重型肝炎中医证型辨证标准探析[J].时珍国医国药,2009,1(20)：133-135.
[55]张涛,孙克伟,黄顺玲.基于特异性细胞免疫学机理阐述慢性重型肝炎中医黄疸论治.中西医结合肝病杂志,2010,20(5)：260-262.
[56]金晓东、张鸣、谭兰香等.慢性重型肝炎中医证型与肝功能及PTA相关性研究[J].国医论坛,2011,26(4)：18-19.
[57]王立福,李筠,李丰衣等.中医辨证联合西药治疗慢加急性(亚急性)肝衰竭多中心随机对照研究[J],中医杂志,2013,54(22)：89-91.
[58]周双男,张宁,李立福等.乙型肝炎相关肝衰竭中西医结合治疗临床研究[J].肝脏,2012,17(1)：36-38.
[59]王立福,李丰衣,周双男等.中西医结合治疗慢性肝衰竭多地域、多中心、随机、对照研究[J].传染病信息,2012,25(3)：155-157.
[60]孙克伟,陈斌,黄裕红,等.凉血解毒、清热化湿和凉血解毒、健脾温阳法治疗慢性重型肝炎43例临床观察[J].中国中西医结合杂志,2006,26(11)：981-983.
[61]孙克伟 龚磊 陈斌 黄裕红等温法干预治疗慢性乙型重型肝炎阳黄湿热内蕴(湿重于热)证的临床疗效与安全性研究.中西医结合肝病杂志.2010,20(3)：135-137
[62]张涛,吉婧,纪恩茹等.乙型肝炎相关性肝衰竭阴、阳黄证患者外周血DCs功能比较研究[J].世界科学技术-中医药现代化,2013,15(5)：813-817.
[63]朱文芳,孙克伟,陈斌等.乙型肝炎相关性肝衰竭不同黄疸证的肠道菌群分析[J],2013,33(1)：128-131.
[64]张智勇,卢绮萍,陈孝平.肝脏缺血及再灌注时胃肠道动力、胃电图变化及丹参预处理的临床研究[J].中华实验外科杂志,2013,30(2)：282-284.
[65]刘晓蓉,徐杰,任新生.丹参肠内营养制剂对S-MODS模型大鼠肠粘膜上皮细胞保护作用的研究[J].肠外与肠内营养,2011,18(1)：35-38.
[66]贺琴,李金科,李芳等清热凉血药赤芍及其组方防治肝病的实验和临床研究进展[J].中国中医急诊,2013,22(10)：1749-1751.
[67]蔡华丹,张慧芹,续畅等.茵陈蒿汤水提物和醇提物活性组分的差异及对D-Ga1N诱导大鼠急性肝损伤预防作用的比较[J].中国实验方剂学杂志,2013,19(10)：251-254.
[1]章晓联.病毒免疫学[M].北京：科学技术出版社,2010.
[2]舒红兵.抗病毒天然免疫[M].北京：科学技术出版社,2009.
[3]邢同京,徐洪涛.肝脏免疫学[M].北京：科学技术文献出版社,2010.
[4]Medzhitov R,Preston-Hurlburt P,Janeway CA Jr. A human homologne of the Drosophila TOH protein signals activation of adaptive immunity, Nature,1997,388:394-397.
[5]Lee M S. Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu RevBiochem.2007,76:447—80.
[6]Abe T.Kaname Y.Hamamoto I,et al.Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor MyD88-dependent signaling pathway in macrophage.cell fines,J Virol,2007,81f17):8953.66.
[7]Yokota S,Okabayashi T,Yokosawa N,et al.M easles virus P protein suppresses Toll-like receptor signal through up-regulation ofubiquitin-modifying enzyme A20.Faseb J,2008,22(1):74-83.
[8]Carmody RJ.Chen YH.Nuclear factor-kappaB:activation and regulation during toll-like receptor signaling.Cell Mollmlnunol,2007,4(1):31-41.
[9]张艳霞,王质刚.人类Toll样受体信号传导途径及其介导的免疫作用[J].国际免疫学杂志,2010,33：121—123.
[10]Zhang SYJouanguy E,Sancho—Shimizu V,et al. HumanTol--like receptor-dependent induction of interferons in protective immunity to viruses. Imm unol Rev,2007,220:225-36-
[11]周运恒.SOCS在原发胆汁性肝硬化发病机制中的作用研究[D].2009：2.
[12]李兰娟等.慢性重型肝炎患者肠道菌群的变化[J].中华传染病杂志,2001,6(19)：345-347.
[13]钟田雨等.利用荧光共振能量转移技术研究活细胞TLR4与MD2作用结构域[J].生物化学和生物物理进展,2009,36(11)：1451-1456.
[14]王慧等.Toll样受体4在慢性乙型肝炎病毒感染者外周血单个核细胞中的表达及意义[J].中华传染病杂志,2007,5(25)：298-301.
[15]Wu J,Lu M,Meng I,et al.Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells inmice[J]Hepatology,2007,46(6):1769-1778.
[16]叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击.中华肝脏病杂志,2009,17(8)：638-640.
[17]徐道振.病毒性肝炎临床实践.北京：人民卫生出版社,2006：266271.
[18]Jerala R. Structural biology of the LPS recognition. Int J Med Microbiol,2007, 297 (5):353—363.
[19]Dajani R, Sanlioglu S, Zhang Y, et al. Pleiotropic functions of TNF-alpha determine distinct IKKbeta-dependent hepato-cellular fates in response to LPS. Am J Physiol Gastrointest Liver Physiol,2007,292(1):242—252.
[20]Chen LC, Gordon RE, Laskin JD, et al. Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemia. Exp Mol Pathol, 2007,83(3):311-326.
[21]El Kasmi KC, Anderson AL, Devereaux MW,et al. Toll like receptor 4 dependent kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition. Hepatology.2011,10:1002-1006.
[22]Braet F, Wisse E. Structural and functional aspects ofliver sinusoidal end—othelial cell fenestrae:a review. Comp Hepatol,2002,1:1-3.
[23]Levy GA,Liu MF,Ding JW,et al. Molecular and functional analysis of human prothrombinase gene (HFGL2) and its role in viral hapetitisl AmJ Pathol, 2000,156(4):1217-1225.
[24]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol.2010,25(5):1009-1012.
[25]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol. 2009,24(6):1089-1094.
[26]杨宏志,肖阁敏,戴敏,等.慢性乙型重型肝炎中医证候的动态观察.中药材,2010,33(9)：1519-1521.
[27]彭杰,陈斌,孙克伟,等,慢性乙型重型肝炎“湿热-血瘀-脾虚”证候分布与演变特点的回顾性分析.中西医结合肝病杂志,2011,21(3)：135-138.
[28]过建春,荀运浩,段传荣,等.慢性乙型重型肝炎中医证候规律研究.中华中医药学刊,2011,29(5)：969-971.
[29]李筠.内毒素在肝衰竭形成中的作用及中医药治疗.传染病信息,2010,23(5)：260-262.
[30]彭春荣,涂显琴,马超英.国内中医药治疗内毒素血症的研究进展.中华中医药学刊,2010,28(11)：2299-2230.
[31]孙克伟,陈斌,黄裕红,等.凉血解毒、清热化湿和凉血解毒、健脾温阳法治疗慢性重型肝炎的临床观察.中国中西医结合杂志,2006,26(11)：981-983.
[32]陈斌,黄裕红,龚磊,等.健脾温阳与清热化湿法治疗血浆置换术后慢性重型肝炎的临床比较.中西医结合肝病杂志,2008,18(6)：368-370.
[1]王慧芬,辛绍杰.肝衰竭诊治进展[M].北京：人民军医出版社,2011：28.
[2]wong V & M Chan HL. Severe acutc exacerbation of chmnic hepatitis B:a unique presentation of a common disease.Gastroenterol Hepatol,2009,24:1179-1186.
[3]Sarin SK,KumarA,AlmeidaJA,etal.Acute-on-chmIlicliverfailure consensus rccommendatjons of the Asjan Pacifjc Association for tile study of tlle liver(APASL).HepatolInt,2009,3:269-282.
[4]刘旭华,郑素军,祖可佳等.91例慢性乙型重型肝炎肝衰竭患者的临床病理分析[J].中华肝脏病杂志,2010,18(10)：721-725.
[5]王柯心.慢性乙型重型肝炎不同分期的中医证候规律研究[D].2010：17.
[6]宓余强,伍喜良,曹武奎等.72例慢性乙型重型肝炎症状与舌脉象聚类分析[J].传染病信息,2010,23(5)：276-278.
[7]李瀚旻.慢性重型肝炎黄疸证候演变规律[J].中西医结合肝病杂志,2009,19(3)：148-149.
[8]熊焰、彭忠平、王书杰.慢性乙型重型肝炎辨证分型研究[J].中医药导报,2010,16(10)：6-9.
[9]刘绍能,陶夏平,王融冰等.慢性乙型肝炎中医证候演变规律研究[J].中国中医药科技,2008,15(3)：161-163.
[10]张肠,谭善忠.慢性重型肝炎／肝衰竭的中医病因病机特点研究进展[J].中西医结合肝病杂志,2011,21(6)：380-383.
[11]李丰衣,王立福,张晓峰等.乙型肝炎肝衰竭中医证候数据库的建立[J].实用肝脏病杂志,2011,14(4)：270-272.
[12]郭蕾,王学伟,王永炎等.论高维高阶与证候的复杂性[J].中华中医药杂志,2006,21(2)：76-78.
[13]朱文锋,张华敏.“证素”的基本特征.中国中医基础医学杂志,2005,11(1)：17-18.
[14]王荣田,樊新荣,黄碧群等.论证素辨证的层次性与实用性[J].中国中医药信息杂志,2008,15(8)：11-12
[15]刘艳,陈丽云,卫洪昌.证型标准化研究的文献统计分析方法学探讨[J].江西中医学院学报,2009,21(2)：88-89.
[16]姚乃礼,中医症状鉴别诊断学[M],北京：人民卫生出版社,2004.
[17]李瀚旻.慢性重型肝炎黄疸证候演变规律[J].中西医结合肝病杂 志,2009,19(3)：148-149.
[18]张涛,孙克伟,陈斌等.黄疸病阴阳学说初探[J].新中医,2011,1(43)：4-6.
[19]彭杰、陈斌、孙克伟等.慢性乙型重型肝炎“湿热-血瘀-脾虚”证候分布与演变特点的回顾性分析[J].中西医结合肝病杂志,2011,21(3)：135-136.
[20]陈玮、刘政芳、林恢等.慢性乙型重型肝炎中医辨证虚实属性与生化指标的相关性分析[J].传染病信息,2010,23(10)：273-275.
[21]李筠.慢性重型肝炎中医辨证与临床分期及预后分析[J].中西医结合肝病杂志,2007,17(6)：343-345.
[22]阮连国,朱清静.慢性乙型重型肝炎“毒、瘀、虚”病因病机及治疗思路探讨[J].湖北中医杂志,2012,34(3)：30-32.
[23]谌宁生,孙克伟.重症肝炎从快速截断论治[J].新中医,2001,33(1)：3-4.
[24]王柯心、关卫兵、戴敏等.慢性乙型重型肝炎不同分期的中医证候规律研究[J].传染病信息,2010,23(5)：266-267.
[25]李芹,张良宏,刘政芳等.慢性重型肝炎120例中医证型分析[J].陕西中医学院学报,2010,33(1)：20-21.
[26]徐庆年、杨宗国、陈晓蓉等.慢性重型肝炎发病特点及与中医证型相关性的临床分析[J].2011,24(9)：43-45.
[27]荀运浩,过建春,陈芝芸等.湿热及阴虚体质与慢性乙型重型肝炎发病的关系[J].中华中医药杂志,2011,26(7).
[28]金晓东、张鸣、谭兰香等.慢性重型肝炎中医证型与肝功能及PTA相关性研究[J].国医论坛,2011,26(4)：18-19.
[29]郭晓丽.乙型慢性重型肝炎中医证型与预后模型及相关指标研究[D].2010：30.
[30]郑亚江,高月求.脾虚型慢性乙型肝炎患者树突细胞功能的变化[J].上海中医药杂志,2008,42(6)：19-22.
[31]张佳莹,李秀惠.慢性乙型重型肝炎证候规律文献统计分析[c].世界中联第四届肝病国际学术大会暨海峡两岸中医肝病研讨会论文集.2011：162-165.
[2]wong V & M Chan HL. Severe acute exacerbation of chmnic hepatitis B:a unique presentation of a common disease.Gastroenterol Hepatol,2009,24:1179-1186.
[3]王柯心.慢性乙型重型肝炎不同分期的中医证候规律研究[D].广州,中山大学,硕士学位论文,2010年.
[4]李筠.慢性重型肝炎证候规律及中西医结合治疗方案研究研究报告.第二十次全国中西医结合肝病学术会议论文集,2011,27-29.
[5]黄建荣.重型乙型病毒性肝炎临床治疗进展.中华医学会第十五次全国病毒性肝炎和肝病学术会议论文集,2011,43-44.
[6]李筠.慢性重型肝炎证候规律及中西医结合治疗方案研究研究报告[R].第二十次全国中西医结合肝病学术会议论文集,2011,27-29.
[7]张雷,李筠.中医药治疗慢性重型肝炎临床研究进展.中西医结合肝病杂志,2010,20(5)：317-319.
[8]周意,贺希.慢性乙型重型肝炎中医证候与临床分期相关性研究[J].中医药导报,2010,5(16)：39-40.
[9]张涛,孙克伟,黄顺玲.基于特异性细胞免疫学机理阐述慢性重型肝炎中医黄疸论治.中西医结合肝病杂志,2010,20(5)：260-262.
[10]De-Wu Han.Intestinal endotoxemia as a pathogenetic mechanism in liver failure [J]世界胃肠病学杂志(英文版),2002,8(6)：961-965.
[11]熊焰、彭忠平、王书杰.慢性乙型重型肝炎辨证分型研究[J].中医药导报,2010,16(10)：6-9.
[12]张涛,孙克伟,陈斌等.黄疸病阴阳学说初探[J].新中医,2011,1(43)：4-6.
[13]李筠.慢性重型肝炎中医辨证与临床分期及预后分析[J].中西医结合肝病杂志,2007,17(6)：343-345.
[14]王荣田,樊新荣,黄碧群等.论证素辨证的层次性与实用性[J].中国中医药信息杂志,2008,15(8)：11-12.
[15]熊焰,彭忠平,王书杰.慢性乙型重型肝炎辨证分型研究[J].中医药导报,2010,10(16)6-9.
[16]陈斌,孙克伟,彭杰,等.基于阳黄-阴阳黄-阴黄辨证模式治疗慢性重型肝炎的临床观察[J].中国中医药科技,2012,19(1)：57-58.
[17]王立福,李筠,李丰衣等.中医辨证联合西药治疗慢加急性(亚急性)肝衰竭多 中心随机对照研究[J],中医杂志,2013,,54(22)：89-91.
[18]卢琳琳,陆伟,胡东胜等.急性肝衰竭大鼠肠粘膜屏障功能变化特点分析[J].山东医药,2012,52(39)：51-53.
[19]马文峰,周小舟,孙新锋等.中药治疗肝衰竭患者内毒素血症及其检测方法[J].中西医结合肝病杂志,2013,23,(2)：107-120.
[20]成薇婷,田德英.D-氨基半乳糖大鼠急性肝衰竭并发内毒素血症对糖代谢的影响极其机制[J].中西医结合肝病杂志,2010,20(1)：38-40.
[21]陈立艳,段钟平,周莉,等.肝功能衰竭模型的研究进展[J].中华肝脏病杂志.2010,18(10)：798-800.
[22]Wang LK,Wang LW,Li x,et al. Ethyl pyruvate prevents inflammatory factors release and dec-reases intestinal permeability in rats with D-galactosamine-induced acute liver failure[J]. Hepatob-iliary & Pancreatic Diseases International,2013,12(2):180-188.
[23]中华医学会感染病学分会肝衰竭与人工肝学组、中华医学会肝病学分会重型肝病与人工肝学组,肝衰竭诊治指南(2010版),中华肝脏病杂志,2011,21(3)：177-183.
[24]顾玉荣,慢加急肝衰竭肠道菌群与系统免疫相关性的初步探讨—慢加急肝衰竭(ACLF)不同时期肠道菌群、血浆内毒素、宿主系统免疫的动态变化及其相关性的初步探讨[D],广州,中山大学,硕士学位论文,2010.
[25]张赤志,曾浩,程良斌.阴黄证动物模型的建立及其意义[J],中国中医基础医学杂志,2000,6(7)：43-45。
[26]刘鹏,张涛,熊焰.乙型肝炎相关性肝衰竭中医证型研究现状[J]医学综述,2013,19(15)：2810-2812.
[27]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol.2010,25(5):1009-1012.
[28]李筠.内毒素在肝衰竭形成中的作用及中医药治疗[J].传染病信息,2010,(5)：260-262
[29]Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways:a dynamic duo. Annu Rev Physiol,2011,73:283-309.
[30]Hocher B,Heiden S,VonWebsky K,et al.Dual endothelin-converting enzyme/Neutral endopep-tidase blockade in rats with D-galactosamine-induced liver failure[J].Europea journal of medical research,2011,16 (6):275-279.
[31]施文娟,成军.HBV相关慢加急性肝功能衰竭患者血清IL-4和IL-6的表达及临 床意义[J].中华实验和临床感染病杂志,2013,7(2)：75-78.
[32]毛德文,张荣臻,邱华等.大黄、赤芍对术后肝衰竭大鼠血清IL-6的影响[J].辽宁中医杂志,2011,38(4)：757-758.
[33]王琳琳,陈秀奇.肠道-肝脏屏障的防御与内毒素移位的干预.临床儿科杂志,2010,28(10)：912-915.
[34]Matsumura F, Hartshorne DJ.Myosin phosphatase target subunit:Many roles in cell function. Biochem Biophys Res Commun,2008,369(1):149-156.
[35]杨宏志,肖阁敏,戴敏等.慢性乙型重型肝炎中医证候的动态观察.中药材,2010,33(9)：1519-1521.
[36]彭春荣,涂显琴,马超英.国内中医药治疗内毒素血症的研究进展.中华中医药学刊,2010,28(11)：2299-2230.
[37]李筠.内毒素在肝衰竭形成中的作用及中医药治疗.传染病信息,2010,23(5)：260-262.
[38]张涛,孙克伟,陈斌等.黄疸病阴阳学初探[J].新中医,2011,43(1)：4-6.
[39]王轩,陈斌,彭杰等.温阳解毒化瘀颗粒对肝衰竭内毒素血症大鼠肠道sIgA的影响[J].中西医结合肝病杂志,2013,23(3)：157-159.
[40]陈斌,王杰,彭杰等.温阳解毒化瘀颗粒对肝衰竭肠源性内毒素血症大鼠TLR4、NF-KB表达的影响[J].世界科学技术-中医药现代化,,2013,15,(5)：818-824.
[41]张强,孙凤霞.急性、亚急性肝衰竭临床研究进展[J].中华实验和临床感染病杂志,2012,6(2)：165-167.
[42]杨柳,赵瑛.川芎嗪对大鼠肠缺血再灌注损伤保护作用的实验研究[J].中国现代药物应用,2008,10(11)：11-15.
[43]梁育岑,段绍斌,刘郁等.大黄对肝部分切除大鼠血清与回肠组织SOD活性及回肠结构的影响[J].新疆医科大学学报,2010,33(1)：16-19.
[44]曲长江,王文丽,吴谙诏,秦微等.中医黄疸动物模型的建立[J].辽宁中医杂志,2005,32(10)：1087-1089.
[45]陈智.肝衰竭发生与发展过程中的免疫机制研究进展[J].中华肝脏病杂志,2012,20(10)：733-736.
[46]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats With Dga-lactosa mine induced acute severe liver injury[J].Gastroenterol Hepatol. 2009,24(6):1089-1094.
[47]伍玉南,孙克伟,彭建平,等.解毒化瘀温阳健脾与解毒化瘀益气健脾法治疗慢性重型肝炎的临床观察[J].中西医结合肝病杂志,2011,21(1)：4-7.
[48]过建春,荀运浩,段传荣等.慢性乙型重型肝炎中医证候规律研究.中华中医药学刊[J].2011,29(5)：969-971.
[49]彭杰,陈斌,孙克伟,等,慢性乙型重型肝炎“湿热-血瘀-脾虚”证候分布与演变特点的回顾性分析.中西医结合肝病杂志,2011,21(3)：135-138.
[50]张秋云等.慢乙肝、肝硬化、乙型慢重肝黄疸病的证候规律研究[J].北京中医药,2009,12(28)：976-978.
[51]周意,贺希.慢性乙型重型肝炎中医证候与临床分期相关性研究[J].中医药导报,2010,5(16)：39-40.
[52]聂广,余绍勇,江福生等.重型肝炎中医辨证分型标准的初步研究[J].中国中西医结合急救杂志,2001,3(8)：172-176.
[53]金晓东,谭兰香等.慢性重型肝炎中医证型与肝功能及PTA相关性研究[J].国医论坛,2011,4(26)：18-19.
[54]龙富立,毛德文等.重型肝炎中医证型辨证标准探析[J].时珍国医国药,2009,1(20)：133-135.
[55]张涛,孙克伟,黄顺玲.基于特异性细胞免疫学机理阐述慢性重型肝炎中医黄疸论治.中西医结合肝病杂志,2010,20(5)：260-262.
[56]金晓东、张鸣、谭兰香等.慢性重型肝炎中医证型与肝功能及PTA相关性研究[J].国医论坛,2011,26(4)：18-19.
[57]王立福,李筠,李丰衣等.中医辨证联合西药治疗慢加急性(亚急性)肝衰竭多中心随机对照研究[J],中医杂志,2013,54(22)：89-91.
[58]周双男,张宁,李立福等.乙型肝炎相关肝衰竭中西医结合治疗临床研究[J].肝脏,2012,17(1)：36-38.
[59]王立福,李丰衣,周双男等.中西医结合治疗慢性肝衰竭多地域、多中心、随机、对照研究[J].传染病信息,2012,25(3)：155-157.
[60]孙克伟,陈斌,黄裕红,等.凉血解毒、清热化湿和凉血解毒、健脾温阳法治疗慢性重型肝炎43例临床观察[J].中国中西医结合杂志,2006,26(11)：981-983.
[61]孙克伟 龚磊 陈斌 黄裕红等温法干预治疗慢性乙型重型肝炎阳黄湿热内蕴(湿重于热)证的临床疗效与安全性研究.中西医结合肝病杂志.2010,20(3)：135-137
[62]张涛,吉婧,纪恩茹等.乙型肝炎相关性肝衰竭阴、阳黄证患者外周血DCs功能比较研究[J].世界科学技术-中医药现代化,2013,15(5)：813-817.
[63]朱文芳,孙克伟,陈斌等.乙型肝炎相关性肝衰竭不同黄疸证的肠道菌群分析[J],2013,33(1)：128-131.
[64]张智勇,卢绮萍,陈孝平.肝脏缺血及再灌注时胃肠道动力、胃电图变化及丹参预处理的临床研究[J].中华实验外科杂志,2013,30(2)：282-284.
[65]刘晓蓉,徐杰,任新生.丹参肠内营养制剂对S-MODS模型大鼠肠粘膜上皮细胞保护作用的研究[J].肠外与肠内营养,2011,18(1)：35-38.
[66]贺琴,李金科,李芳等清热凉血药赤芍及其组方防治肝病的实验和临床研究进展[J].中国中医急诊,2013,22(10)：1749-1751.
[67]蔡华丹,张慧芹,续畅等.茵陈蒿汤水提物和醇提物活性组分的差异及对D-Ga1N诱导大鼠急性肝损伤预防作用的比较[J].中国实验方剂学杂志,2013,19(10)：251-254.
[1]章晓联.病毒免疫学[M].北京：科学技术出版社,2010.
[2]舒红兵.抗病毒天然免疫[M].北京：科学技术出版社,2009.
[3]邢同京,徐洪涛.肝脏免疫学[M].北京：科学技术文献出版社,2010.
[4]Medzhitov R,Preston-Hurlburt P,Janeway CA Jr. A human homologne of the Drosophila TOH protein signals activation of adaptive immunity, Nature,1997,388:394-397.
[5]Lee M S. Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu RevBiochem.2007,76:447—80.
[6]Abe T.Kaname Y.Hamamoto I,et al.Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor MyD88-dependent signaling pathway in macrophage.cell fines,J Virol,2007,81f17):8953.66.
[7]Yokota S,Okabayashi T,Yokosawa N,et al.M easles virus P protein suppresses Toll-like receptor signal through up-regulation ofubiquitin-modifying enzyme A20.Faseb J,2008,22(1):74-83.
[8]Carmody RJ.Chen YH.Nuclear factor-kappaB:activation and regulation during toll-like receptor signaling.Cell Mollmlnunol,2007,4(1):31-41.
[9]张艳霞,王质刚.人类Toll样受体信号传导途径及其介导的免疫作用[J].国际免疫学杂志,2010,33：121—123.
[10]Zhang SYJouanguy E,Sancho—Shimizu V,et al. HumanTol--like receptor-dependent induction of interferons in protective immunity to viruses. Imm unol Rev,2007,220:225-36-
[11]周运恒.SOCS在原发胆汁性肝硬化发病机制中的作用研究[D].2009：2.
[12]李兰娟等.慢性重型肝炎患者肠道菌群的变化[J].中华传染病杂志,2001,6(19)：345-347.
[13]钟田雨等.利用荧光共振能量转移技术研究活细胞TLR4与MD2作用结构域[J].生物化学和生物物理进展,2009,36(11)：1451-1456.
[14]王慧等.Toll样受体4在慢性乙型肝炎病毒感染者外周血单个核细胞中的表达及意义[J].中华传染病杂志,2007,5(25)：298-301.
[15]Wu J,Lu M,Meng I,et al.Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells inmice[J]Hepatology,2007,46(6):1769-1778.
[16]叶一农,高志良.乙型肝炎肝衰竭发生机制中的三重打击.中华肝脏病杂志,2009,17(8)：638-640.
[17]徐道振.病毒性肝炎临床实践.北京：人民卫生出版社,2006：266271.
[18]Jerala R. Structural biology of the LPS recognition. Int J Med Microbiol,2007, 297 (5):353—363.
[19]Dajani R, Sanlioglu S, Zhang Y, et al. Pleiotropic functions of TNF-alpha determine distinct IKKbeta-dependent hepato-cellular fates in response to LPS. Am J Physiol Gastrointest Liver Physiol,2007,292(1):242—252.
[20]Chen LC, Gordon RE, Laskin JD, et al. Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemia. Exp Mol Pathol, 2007,83(3):311-326.
[21]El Kasmi KC, Anderson AL, Devereaux MW,et al. Toll like receptor 4 dependent kupffer cell activation and liver injury in a novel mouse model of parenteral nutrition. Hepatology.2011,10:1002-1006.
[22]Braet F, Wisse E. Structural and functional aspects ofliver sinusoidal end—othelial cell fenestrae:a review. Comp Hepatol,2002,1:1-3.
[23]Levy GA,Liu MF,Ding JW,et al. Molecular and functional analysis of human prothrombinase gene (HFGL2) and its role in viral hapetitisl AmJ Pathol, 2000,156(4):1217-1225.
[24]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol.2010,25(5):1009-1012.
[25]Kitazawa T, Tsujimoto T, Kawaratani H,et al, Therapeutic approach to regulate innate immune response by Toll-like receptor 4 antagonist E5564 in rats with D-galactosamine-induced acute severe liver injury. J Gastroenterol Hepatol. 2009,24(6):1089-1094.
[26]杨宏志,肖阁敏,戴敏,等.慢性乙型重型肝炎中医证候的动态观察.中药材,2010,33(9)：1519-1521.
[27]彭杰,陈斌,孙克伟,等,慢性乙型重型肝炎“湿热-血瘀-脾虚”证候分布与演变特点的回顾性分析.中西医结合肝病杂志,2011,21(3)：135-138.
[28]过建春,荀运浩,段传荣,等.慢性乙型重型肝炎中医证候规律研究.中华中医药学刊,2011,29(5)：969-971.
[29]李筠.内毒素在肝衰竭形成中的作用及中医药治疗.传染病信息,2010,23(5)：260-262.
[30]彭春荣,涂显琴,马超英.国内中医药治疗内毒素血症的研究进展.中华中医药学刊,2010,28(11)：2299-2230.
[31]孙克伟,陈斌,黄裕红,等.凉血解毒、清热化湿和凉血解毒、健脾温阳法治疗慢性重型肝炎的临床观察.中国中西医结合杂志,2006,26(11)：981-983.
[32]陈斌,黄裕红,龚磊,等.健脾温阳与清热化湿法治疗血浆置换术后慢性重型肝炎的临床比较.中西医结合肝病杂志,2008,18(6)：368-370.
[1]王慧芬,辛绍杰.肝衰竭诊治进展[M].北京：人民军医出版社,2011：28.
[2]wong V & M Chan HL. Severe acutc exacerbation of chmnic hepatitis B:a unique presentation of a common disease.Gastroenterol Hepatol,2009,24:1179-1186.
[3]Sarin SK,KumarA,AlmeidaJA,etal.Acute-on-chmIlicliverfailure consensus rccommendatjons of the Asjan Pacifjc Association for tile study of tlle liver(APASL).HepatolInt,2009,3:269-282.
[4]刘旭华,郑素军,祖可佳等.91例慢性乙型重型肝炎肝衰竭患者的临床病理分析[J].中华肝脏病杂志,2010,18(10)：721-725.
[5]王柯心.慢性乙型重型肝炎不同分期的中医证候规律研究[D].2010：17.
[6]宓余强,伍喜良,曹武奎等.72例慢性乙型重型肝炎症状与舌脉象聚类分析[J].传染病信息,2010,23(5)：276-278.
[7]李瀚旻.慢性重型肝炎黄疸证候演变规律[J].中西医结合肝病杂志,2009,19(3)：148-149.
[8]熊焰、彭忠平、王书杰.慢性乙型重型肝炎辨证分型研究[J].中医药导报,2010,16(10)：6-9.
[9]刘绍能,陶夏平,王融冰等.慢性乙型肝炎中医证候演变规律研究[J].中国中医药科技,2008,15(3)：161-163.
[10]张肠,谭善忠.慢性重型肝炎／肝衰竭的中医病因病机特点研究进展[J].中西医结合肝病杂志,2011,21(6)：380-383.
[11]李丰衣,王立福,张晓峰等.乙型肝炎肝衰竭中医证候数据库的建立[J].实用肝脏病杂志,2011,14(4)：270-272.
[12]郭蕾,王学伟,王永炎等.论高维高阶与证候的复杂性[J].中华中医药杂志,2006,21(2)：76-78.
[13]朱文锋,张华敏.“证素”的基本特征.中国中医基础医学杂志,2005,11(1)：17-18.
[14]王荣田,樊新荣,黄碧群等.论证素辨证的层次性与实用性[J].中国中医药信息杂志,2008,15(8)：11-12
[15]刘艳,陈丽云,卫洪昌.证型标准化研究的文献统计分析方法学探讨[J].江西中医学院学报,2009,21(2)：88-89.
[16]姚乃礼,中医症状鉴别诊断学[M],北京：人民卫生出版社,2004.
[17]李瀚旻.慢性重型肝炎黄疸证候演变规律[J].中西医结合肝病杂 志,2009,19(3)：148-149.
[18]张涛,孙克伟,陈斌等.黄疸病阴阳学说初探[J].新中医,2011,1(43)：4-6.
[19]彭杰、陈斌、孙克伟等.慢性乙型重型肝炎“湿热-血瘀-脾虚”证候分布与演变特点的回顾性分析[J].中西医结合肝病杂志,2011,21(3)：135-136.
[20]陈玮、刘政芳、林恢等.慢性乙型重型肝炎中医辨证虚实属性与生化指标的相关性分析[J].传染病信息,2010,23(10)：273-275.
[21]李筠.慢性重型肝炎中医辨证与临床分期及预后分析[J].中西医结合肝病杂志,2007,17(6)：343-345.
[22]阮连国,朱清静.慢性乙型重型肝炎“毒、瘀、虚”病因病机及治疗思路探讨[J].湖北中医杂志,2012,34(3)：30-32.
[23]谌宁生,孙克伟.重症肝炎从快速截断论治[J].新中医,2001,33(1)：3-4.
[24]王柯心、关卫兵、戴敏等.慢性乙型重型肝炎不同分期的中医证候规律研究[J].传染病信息,2010,23(5)：266-267.
[25]李芹,张良宏,刘政芳等.慢性重型肝炎120例中医证型分析[J].陕西中医学院学报,2010,33(1)：20-21.
[26]徐庆年、杨宗国、陈晓蓉等.慢性重型肝炎发病特点及与中医证型相关性的临床分析[J].2011,24(9)：43-45.
[27]荀运浩,过建春,陈芝芸等.湿热及阴虚体质与慢性乙型重型肝炎发病的关系[J].中华中医药杂志,2011,26(7).
[28]金晓东、张鸣、谭兰香等.慢性重型肝炎中医证型与肝功能及PTA相关性研究[J].国医论坛,2011,26(4)：18-19.
[29]郭晓丽.乙型慢性重型肝炎中医证型与预后模型及相关指标研究[D].2010：30.
[30]郑亚江,高月求.脾虚型慢性乙型肝炎患者树突细胞功能的变化[J].上海中医药杂志,2008,42(6)：19-22.
[31]张佳莹,李秀惠.慢性乙型重型肝炎证候规律文献统计分析[c].世界中联第四届肝病国际学术大会暨海峡两岸中医肝病研讨会论文集.2011：162-165.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |